Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Select your state to see jurisdictional framework, reporting obligations, and authority links. Substance information above is the same in every state.
Seizures Clinical criteria: The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient, AND Patient must have focal onset seizures; OR Patient must have primary generalised tonic-clonic seizures; OR Patient must have seizures of the Lennox-Gastaut syndrome, AND The condition must have failed to be controlled satisfactorily by at least one other antiseizure medication, AND Patient must be unable to take a solid dose form of topiramate. Treatment criteria: Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) an authorised PBS prescriber who is not a medical practitioner, but who is: (a) sharing care of the patient with at least one medical practitioner; (b) intending to share care of the patient with a medical practitioner.
“Topiramate reduces the frequency at which action potentials are generated when neurons are subjected to a sustained depolarisation, which is indicative of a state dependent blockade of voltage-sensitive sodium channels.”
“Following administration of multiple doses of 50 mg and 100 mg of topiramate twice a day, the mean plasma elimination half-life was approximately 21 hours.”
Working under the parallel aged-care framework? Aged-care equivalent →
Migraine Clinical criteria: The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient, AND The treatment must be for prophylaxis, AND Patient must have experienced an average of 3 or more migraines per month over a period of at least 6 months, AND Patient must have a contraindication to beta-blockers, as described in the relevant TGA-approved Product Information; OR Patient must have experienced intolerance of a severity necessitating permanent withdrawal during treatment with a beta-blocker, AND Patient must have a contraindication to pizotifen because the weight gain associated with this drug poses an unacceptable risk; OR Patient must have experienced intolerance of a severity necessitating permanent withdrawal during treatment with pizotifen. Details of the contraindication and/or intolerance(s) must be documented in the patient's medical records when treatment is initiated.
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“This is possibly due to inhibition of a specific enzyme polymorphic isoform (CYP2C19).”